Uniqure NV (NASDAQ:QURE) has earned an average rating of “Buy” from the nine research firms that are currently covering the company. Three research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12-month price target among brokers that have covered the stock in the last year is $12.45.
Several brokerages recently issued reports on QURE. Zacks Investment Research upgraded shares of Uniqure NV from a “hold” rating to a “buy” rating and set a $6.75 price objective on the stock in a report on Friday, January 6th. Oppenheimer Holdings Inc. set a $17.00 price target on shares of Uniqure NV and gave the stock a “buy” rating in a research note on Sunday, December 25th. Jefferies Group LLC reiterated a “hold” rating and set a $8.00 price target on shares of Uniqure NV in a research note on Wednesday, April 12th. Finally, Chardan Capital reiterated a “positive” rating and set a $12.00 price target on shares of Uniqure NV in a research note on Monday, January 30th.
TRADEMARK VIOLATION WARNING: “Uniqure NV (QURE) Receives Average Recommendation of “Buy” from Analysts” was originally posted by Chaffey Breeze and is owned by of Chaffey Breeze. If you are accessing this article on another publication, it was copied illegally and republished in violation of United States & international trademark & copyright laws. The legal version of this article can be read at https://www.chaffeybreeze.com/2017/04/21/uniqure-nv-qure-receives-average-recommendation-of-buy-from-analysts-updated-updated.html.
Uniqure NV (NASDAQ:QURE) traded down 3.14% during mid-day trading on Monday, hitting $5.25. 88,687 shares of the stock traded hands. Uniqure NV has a 12 month low of $5.15 and a 12 month high of $14.76. The company’s market cap is $132.44 million. The company’s 50 day moving average is $5.88 and its 200 day moving average is $6.30.
A number of institutional investors have recently made changes to their positions in the stock. Perceptive Advisors LLC acquired a new position in shares of Uniqure NV during the fourth quarter worth about $7,089,000. City Financial Investment Co Ltd acquired a new position in shares of Uniqure NV during the fourth quarter worth about $1,492,000. Baker BROS. Advisors LP acquired a new position in shares of Uniqure NV during the third quarter worth about $1,760,000. FMR LLC increased its position in shares of Uniqure NV by 4.1% in the fourth quarter. FMR LLC now owns 1,175,118 shares of the biotechnology company’s stock worth $6,580,000 after buying an additional 46,200 shares during the period. Finally, FT Options LLC increased its stake in Uniqure NV by 116.1% in the fourth quarter. FT Options LLC now owns 65,158 shares of the biotechnology company’s stock valued at $365,000 after buying an additional 35,000 shares during the last quarter. 29.84% of the stock is owned by hedge funds and other institutional investors.
About Uniqure NV
uniQure N.V. (uniQure) is a gene therapy company. The Company is engaged in developing single treatments with curative results for patients suffering from genetic and other severe diseases. The Company is advancing a focused pipeline of gene therapies that have been developed both internally and through partnerships.
Receive News & Ratings for Uniqure NV Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uniqure NV and related companies with MarketBeat.com's FREE daily email newsletter.